Akhlesh K. Jain* and Keerti Mishra
Background: Conventional drug delivery agents for a life-threatening disease, i.e., cancer, lack specificity towards cancer cells, causing serious toxicities in the normal cells and exhibiting poor therapeutic indices. These toxic side effects often limit dose escalation of anti-cancer drugs, leading to incomplete tumor suppression/cancer eradication, early disease relapse, and ultimately, the development of drug resistance. Accordingly, targeting the tumor vasculatures is essential for the treatment of cancer.
Objective: To search and describe a safer drug delivery carrier for the treatment of cancer, with reduced systemic toxicities.
Methods: Data were collected from Medline, PubMed, Google Scholar, Science Direct through the search of the following keywords: ‘liposomes’, ‘nanocarriers’, ‘targeted drug delivery’, ‘ligands’, ‘liposome for anti-cancerous drugs’, ‘treatment for cancer’ and ‘receptor targeting.’
Results: Liposomes have provided a safe platform for the targeted delivery of encapsulated anti-cancer drugs for the treatment of cancer, which results in the reduction of the cytotoxic side effects of anti-cancer drugs on normal cells.
Conclusion: Liposomal targeting is a better emerging approach as an advanced drug delivery carrier with targeting ligands for anti-cancer agents.
Cancer, Anticancer drugs, Nanocarriers, Drug delivery, Liposomes, Ligands, Targeted therapy.
School of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur- 495 009 (C.G.), School of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur- 495 009 (C.G.)